LGC, London, has acquired The Native Antigen Company (NAC), Oxford, UK, one of the world’s leading suppliers of high-quality infectious disease antigens and antibodies.
Nick Roesen, The Native Antigen Company.
NAC is a developer, manufacturer, and supplier of critical reagents to the in vitro diagnostic, pharmaceutical, and academic sectors. It offers a comprehensive portfolio of native and recombinant infectious disease antigens and related products including pathogen receptors, virus-like particles, and antibodies for use in immunoassay applications, vaccine development, and quality control solutions. NAC was one of the first companies globally to offer antigens for SARS-COV-2 and continues to play an important role in supporting the global response to the covid-19 pandemic, according to the company. LGC says the acquisition strengthens its existing product offering to the in vitro diagnostic sector, which includes a range of quality assurance tools, immunoassay reagents, and disease state plasma as well as probes and primers for molecular diagnostics. “NAC is a natural fit with our clinical diagnostics business and will enable us to provide an expanded portfolio of critical reagents to our customers, says Michael Sweatt, executive vice president and general manager, clinical diagnostics, LGC. “NAC’s focus on infectious disease is highly complementary with our existing offer to this segment comprising controls, reference materials, MDx tools, and other components. We are excited to welcome our new colleagues into our organization.” “We are delighted to be joining LGC as an integral part of their fast-growing clinical diagnostics business,” says Nick Roesen, COO of NAC. “Even more so, we are excited to join such a well-respected organization that shares our purpose and mission, and that will support our diagnostic customers by providing even more world-leading products and services.” For more information, visit LGCand The Native Antigen Company.
